RecruitingPhase 4NCT03152890

Insulin Therapy for Postreperfusion Hyperglycemia

Insulin Therapy for Postreperfusion Hyperglycemia in Liver Transplantation


Sponsor

Seoul National University Hospital

Enrollment

20 participants

Start Date

May 15, 2017

Study Type

INTERVENTIONAL

Conditions

Summary

Glycemic control during liver transplantation is challenging especially after reperfusion of the liver graft. Insulin dose to treat postreperfusion hyperglycemia is retrospectively analyzed using historical data. The proposed dose then is prospectively applied to the patients to assess the adequacy of the insulin dose.


Eligibility

Min Age: 19 Years

Inclusion Criteria1

  • Liver recipients who showed hyperglycemia (blood glucose >180mg/dL) after reperfusion of liver graft.

Exclusion Criteria1

  • pediatric patients

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGInsulin

If blood glucose level after reperfusion of liver graft exceeds 180 mg/dL, the insulin dose proposed by the linear mixed effects analysis is given as a bolus.


Locations(1)

Seoul National University Hospital

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03152890


Related Trials